SCHEMBL369854

SCHEMBL369854

COc1ccc(-n2/c(=N\C#N)n(C)c3cnc4ccc(-c5cnc6ccccc6c5)cc4c32)c(OC)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 13/20 0.51
PIK3CD O00329 11/20 0.51
PIK3CB P42338 5/20 0.51
PIK3CG P48736 5/20 0.51
PIK3CA P42336 6/20 0.49
PRKDC P78527 3/20 0.49
ATM Q13315 2/20 0.49
PIK3C2A O00443 2/20 0.49
PIK3C2B O00750 2/20 0.49
CHEK1 O14757 1/20 0.49
ABCB11 O95342 1/20 0.49
CSF1R P07333 1/20 0.49
MET P08581 1/20 0.49
PIK3R1 P27986 1/20 0.49
LTK P29376 1/20 0.49
CDK7 P50613 1/20 0.49
NEK2 P51955 1/20 0.49
JAK3 P52333 1/20 0.49
LIMK1 P53667 1/20 0.49
ACVR1 Q04771 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL369855 1.00 MTOR (0.51) MTORPIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL368332 0.94 PIK3CD (0.44) MTORPIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL368331 0.94 PIK3CD (0.44) MTORPIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL369024 0.87 PIK3CD (0.41) MTORPIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL369025 0.87 PIK3CD (0.41) MTORPIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL368404 0.87 PIK3CD (0.50) MTORPIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL368403 0.87 PIK3CD (0.50) MTORPIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL368433 0.85 PIK3CD (0.46) MTORPIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL368434 0.85 PIK3CD (0.46) MTORPIK3CDPIK3CBPIK3CGPIK3CA
SCHEMBL367467 0.84 NPC1 (0.40) MTORPIK3CDPIK3CBPIK3CGPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593450-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-22 EP claimed
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-09 US claimed
WO-2012007926-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-01-19 WO claimed
US-9062046-B2 Substituted imidazoquinoline derivatives as kinase inhibitors Piramal Enterprises Limited (IN) 2015-06-23 US disclosed
EP-2593450-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-22 EP disclosed
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS Piramal Enterprises Limited (IN) 2013-05-09 US disclosed
WO-2012007926-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116248-A1 SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS CDK2, CDK4, MAP3K1 MTOR 102/4885PIK3CD 115/4885PIK3CB 109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.